Author: Atreya, Chintamani; Glynn, Simone; Busch, Michael; Kleinman, Steve; Snyder, Edward; Rutter, Sara; AuBuchon, James; Flegel, Willy; Reeve, David; Devine, Dana; Cohn, Claudia; Custer, Brian; Goodrich, Raymond; Benjamin, Richard J.; Razatos, Anna; Cancelas, Jose; Wagner, Stephen; Maclean, Michelle; Gelderman, Monique; Cap, Andrew; Ness, Paul
Title: Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026) Document date: 2019_5_29
ID: 0m2ganys_76
Snippet: This ability to directly treat prebagged plasma and PLT blood products using 405-nm light exposure, without the addition of photosensitizer molecules, is highly desirable as it would eliminate the requirement for the additional processing stages needed with other PRTs for passage through equipment and removal of chemical additives, thus reducing cross-contamination risks and also potentially reducing processing times. Thus, further research to ex.....
Document: This ability to directly treat prebagged plasma and PLT blood products using 405-nm light exposure, without the addition of photosensitizer molecules, is highly desirable as it would eliminate the requirement for the additional processing stages needed with other PRTs for passage through equipment and removal of chemical additives, thus reducing cross-contamination risks and also potentially reducing processing times. Thus, further research to expand the understanding and compatibility of this technology with blood transfusion products is warranted.
Search related documents:
Co phrase search for related documents- blood transfusion and light exposure: 1, 2
- blood transfusion and PLT blood: 1, 2, 3
- blood transfusion and removal equipment: 1
- cross contamination risk and light exposure: 1
Co phrase search for related documents, hyperlinks ordered by date